Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-969 in Metastatic Castration-Resistant Prostate Cancer
NCT06318273Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Primary completion
- May 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of ABBV-969 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events at 3 years and Percentage of Participants Achieving Prostate Specific Antigen response at 3 years. Started Mar 2024; status: active, not recruiting.
02
Drugs
ABBV-969
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06318273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318273.